We review advances in risk stratification and therapy for pediatric genitourinary RMS.
Strategies for low-risk RMS aim to reduce toxicity and maintain favorable prognosis.
Prognosis for high-risk disease remains poor, and novel treatments are needed.
Advances in genetic analysis have led to refinement in risk stratification.
Ongoing research holds promise for the development of novel targeted therapies.